OncoMatch/Clinical Trials/NCT03800693
2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
Is NCT03800693 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Fluorouracil and Leucovorin for malignant digestive system neoplasm.
Treatment: Fluorouracil · Leucovorin · Oxaliplatin — This phase II trial studies how well giving oxaliplatin over 6 hours works in treating nerve damage in patients with gastrointestinal cancers. Oxaliplatin can cause side effects such as nerve damage that may delay or reduce the dose of oxaliplatin. Giving oxaliplatin over a longer period of time (6 hours) may prevent or delay the development of nerve damage, which may keep patients on standard doses of chemotherapy longer, without having to delay treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Esophageal Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anticancer therapy
Patients currently receiving anticancer therapies or who have received any focal or systemic anticancer therapy within 14days of the start of FOLFOX6
Cannot have received: investigational drug
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 14days prior to dosing
Lab requirements
Blood counts
ANC ≥ 1,500/µL (no white blood cell growth factors allowed to meet requirement); Platelets ≥ 75,000/µL (may be transfused up to 72 hours prior to day 1 to meet requirement); Hemoglobin ≥ 8 g/dL (may be transfused up to 72 hours prior to day 1 to meet requirement)
Kidney function
Creatinine clearance > 30 mL/min by Cockcroft-Gault
Liver function
Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
Absolute neutrophil count (ANC) ≥ 1,500/µL (no white blood cell growth factors allowed to meet requirement); Platelets ≥ 75,000/µL (may be transfused up to 72 hours prior to day 1 to meet requirement); Hemoglobin ≥ 8 g/dL (may be transfused up to 72 hours prior to day 1 to meet requirement); Creatinine clearance > 30 mL/min by Cockcroft-Gault; Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University Hospital Midtown · Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
- Emory Saint Joseph's Hospital · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify